Convergent ablation for persistent atrial fibrillation: A UK multicentre perspective

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and remains a major cause of morbidity and mortality. Unfortunately, a significant proportion of patients have persistent AF, for which conventional catheter ablation is less effective. However, convergent ablation has emerge...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular electrophysiology Vol. 35; no. 10; pp. 2039 - 2052
Main Authors Mannakkara, Nilanka N., Khan, Ibrar, Ghazanfar, Auns, Wijesuriya, Nadeev, Mehta, Vishal S., De Vere, Felicity, Howell, Sandra, Adhya, Shaumik, Porter, Bradley, Child, Nicholas, Razavi, Reza, Rinaldi, Christopher A., Bosco, Paolo, Blauth, Christopher, Gill, Jaswinder S.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.10.2024
Subjects
Ablation
Arrhythmia
atrial fibrillation
catheter ablation
Electrophysiology
Fibrillation
hybrid ablation
Morbidity
atrial fibrillation
catheter ablation
hybrid ablation
arrhythmia
Online AccessGet full text

Cover

More Information
Summary:Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide and remains a major cause of morbidity and mortality. Unfortunately, a significant proportion of patients have persistent AF, for which conventional catheter ablation is less effective. However, convergent ablation has emerged in recent years as a hybrid treatment targeting both the epicardium and endocardium in a multidisciplinary joint cardiothoracic and electrophysiology procedure, with promising efficacy outcomes in recent studies. This treatment is increasingly being performed in the United Kingdom. This review article discusses the rationale and evidence behind convergent ablation, along with factors that need to be considered when setting up a successful ablation service.
Bibliography:Disclosures
Outside of the submitted work: Nilanka N. Mannakkara is funded by a research grant from Heart Research UK (grant no. RG2701). Felicity De Vere and Nadeev Wijesuriya are in receipt of research funding from British Heart Foundation. Sandra Howell has received educational fellowship funding from EBR systems Inc. Vishal S. Mehta has received educational fellowship funding from Siemens Ltd; Christopher A. Rinaldi has received research funding and/or consultation fees from Abbott, Medtronic, Boston Scientific, Spectranetics and Microport; Christopher Blauth has consulted for New Cardioplegia Solutions and as a proctor for Atricure; Jaswinder S. Gill has received research funding from Abbott and lecture honoraria from Atricure. Other authors: No disclosures.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1045-3873
1540-8167
1540-8167
DOI:10.1111/jce.16399